Schizophrenia might be an autoimmune disease where the body’s own antibodies launch a physical attack on the brain.

The medical community has traditionally viewed schizophrenia as a chemical imbalance or a purely genetic disorder. This research identifies a high burden of autoantibodies in patients that specifically target the central nervous system. These antibodies weaken the blood-brain barrier and interfere with neural signaling in a way that correlates with severe symptoms. Patients with these specific immune markers were also found to be less responsive to standard antipsychotic medications. Shifting the focus toward immunotherapy could offer a brand-new path for treating patients who do not benefit from current psychiatric drugs.